LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Kodu・Aktsiate loetelu・BioNTech SE ADR

BioNTech SE ADR

Suletud

SektorTervishoid

89.38 1.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

87.99

Max

91.01

Põhinäitajad
By Trading Economics
Sissetulek	-239M -541M
Müük	-779M 120M
Aktsiakasum	-1.95
Kasumimarginaal	-450.381
Töötajad	7,807
EBITDA	-481M -549M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+50.9% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-1.9B 23B
Eelmine avamishind	88.27
Eelmine sulgemishind	89.38

Uudiste sentiment

By Acuity

17%

83%

30 / 344 Pingereas Healthcare

BioNTech SE ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. mai 2026, 18:12 UTC

Tulu

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. mai 2026, 13:54 UTC

Tulu

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

10. märts 2026, 12:50 UTC

Tulu

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10. märts 2026, 11:18 UTC

Tulu

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

4. aug 2025, 14:14 UTC

Tulu

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. -- Barrons.com

4. aug 2025, 11:59 UTC

Tulu

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

12. juuni 2025, 14:20 UTC

Omandamised, ülevõtmised, äriostud

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12. juuni 2025, 13:34 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

10. juuni 2025, 12:18 UTC

Tulu

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

BioNTech SE ADR Prognoos

Hinnasiht

By TipRanks

50.9% tõus

12 kuu keskmine prognoos

Keskmine 133.47 USD 50.9%

Kõrge 167 USD

Madal 94 USD

Põhineb 18 Wall Streeti analüütiku instrumendi BioNTech SE ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi BioNTech SE ADR aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

30 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac